PROGRAMME
MARCH 16
| 09:00 | SESSION 1: New discoveries on the mechanism of inhibitor development Chairs: Pier Mannuccio Mannucci (Italy), Donna Di Michele (USA) |
| Roadmap for improved haemophilia treatment Flora Peyvandi (Italy) |
|
| Speed bumps on the innovation highway Donna Di Michele (USA) |
|
| Unexpected guests; Stabilin‐2 as a regulatory factor for inhibitor development David Lillicrap (Canada) |
|
| IDO1 and inhibitor development in hemophilia A Davide Matino (Italy) |
| 10:40 | Coffee break & Poster Session |
| 11:00 | SESSION 1 (continued) Chairs: Jan Voorberg (The Netherlands), Christoph Königs (Germany) |
| Quantification and phenotyping of factor VIII-specific T cells in healthy donors Bernard Maillère (France) |
|
| Antigen presentation in inhibitor development: new discoveries Sébastien Lacroix-Desmazes (France) |
|
| To serve and protect: modulating effect of von Willebrand factor on FVIII peptide presentation Jan Voorberg (The Netherlands) |
| 12:30 | ORAL COMMUNICATION SESSION Industry research Chairs: David Lillicrap (Canada), Elena Santagostino (Italy) |
| Emicizumab prophylaxis in
adolescent/adult patients with haemophilia A previously receiving
episodic or prophylactic bypassing agent treatment: updated analyses
from the HAVEN 1 Study. Maria Elisa Mancuso (Italy) |
|
| Role of rFVIIIFc in immune tolerance induction in severe hemophilia A patients with Inhibitors Nisha Jain (USA) |
|
| Efficacy, safety, and
pharmacokinetics of once-weekly emicizumab prophylaxis in paediatric
persons with haemophilia A (PwHA) with inhibitors two years old or
younger in the HAVEN 2 Study Flora Peyvandi (Italy) |
|
| Low immunogenicity of human-cell-derived recombinant FVIII in previously untreated patients with non-null F8 mutations Anna Pavlova (Germany) |
|
| Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of haemophilia Torben Colberg (USA) |
|
| Real-World safety and benefit of
early treatment with room temperature-stable recombinant activated
Factor VII (rFVIIa) in patients with haemophilia A or B with inhibitors:
SMART-7™ study results Kaan Kavakli (Turkey), on behalf of the SMART-7™ steering committee |
| 13:30 | Lunch |
| 14:30 | SESSION 2: New developments for tolerance induction Chairs: Flora Peyvandi (Italy), Federico Mingozzi (France) |
| Gene therapy and new approaches for tolerance induction Federico Mingozzi (France) Federico Mingozzi (France) |
|
| Liver induced tolerance Percy Knolle (Germany) |
| 15:30 | Coffee break & Poster Session |
| 16:00 | SESSION 2 (continued) Chairs: Luigi Naldini (Italy), David Lillicrap (Canada) |
| Engineering regulatory T cells: Driving CARs to BARs David Scott (USA) |
|
| Perspectives of Immune Tolerance Induction (ITI) in the era of new haemophilia treatment options Johannes Oldenburg (Germany) |
|
| Alternatives to human VIII – orthologs, ancestors and hybrids thereof Christopher B. Doering (USA) |
| 17:30 | WALKING ORAL COMMUNICATIONS SESSION Foyer in front of the Plenary Hall (with refreshments) Chairs: Donna Di Michele (USA), Frits Rosendaal (The Netherlands) |
| Generation and characterization of humanized hemophilic mice expressing HLA-DRB1*0101 Jules Russick (France) |
|
| Recombinant FVIII product type and the risk
of inhibitor development in previously treated patients with hemophilia
A: a systematic review and meta-analysis Shermarke Hassan (The Netherlands) |
|
| SIPPET effect on Turkisk previously untreated patients (PUP) with severe hemophilia A: National data Kaan Kavakli (Turkey) |
|
| Identification and functional
characterization of a novel consensus sequence splicing mutation of
factor VIII (FVIII) coagulation gene associated with severe hemophilia A
and inhibitors development Rosella Famà (Italy) |
|
| Single center experience in the treatment of haemophilia A PUPs Susan Halimeh (Germany) |
|
| Lot-matching decreases the time for Immune Tolerance Induction (ITI): Preliminary results of the ObsITI study Jonathan Ducore (USA) |
|
| Severe acquired von Willebrand syndrome (type 3-like): a case report Francesca Stufano (Italy) |
|
| Discussion and question and answers |
| 19:00 | End of sessions |
MARCH 17
| 09:00 | Lecture: Evolving inhibitor incidence over time Frits R. Rosendaal (The Netherlands) |
| 09:30 | SESSION 3: Treatment of inhibitors in hemophilia Chairs: Sébastien Lacroix-Desmazes (France) and Michael Makris (UK) |
| Development of SerpinPC as a pan-haemophilia agent Jim Huntington (UK) |
|
| Standard and novel approaches for treatment and prevention of bleeding episodes in patients with inhibitors Roseline D’OIRON (France) |
|
| CAR/BAR mediated treatment of haemophilia A Christoph Konigs (Germany) |
| 11:00 | Coffee break |
| 11:30 | SESSION 3 (continued) Chairs: Sébastien Lacroix-Desmazes (France) and Michael Makris (UK) |
| How to measure the efficacy of treatment in patients with inhibitors (Laboratory assays) Steven Kitchen (UK) |
|
| How to manage surgery in inhibitors patients with standard and novel therapies Maria Elisa Mancuso (Italy) |
|
| Conclusive remarks Flora Peyvandi (Italy) |
| 13:00 | End of sessions |